Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Celldex Therapeutics, Inc. (CLDX), ACADIA Pharmaceuticals Inc. (ACAD): Two Biotech Stocks That Could Soon be Acquired

Page 1 of 2

While a company is in the clinical phase of development, there are roughly four catalysts that could move the stock higher.

1. Expansion of intellectual property and patents (creates moderate movement)

2. Partnership (creates moderate-large movement)

3. Phase data (creates large movement)

4. Acquisition (creates largest movement)

The final catalyst is the one that I am reviewing today. I am looking at two companies that look to be attractive acquisition targets. These are companies that have a product or technology that is unique yet effective, and that could add to the product offerings of another larger biopharmaceutical company.

A legitimate contender in the fight against cancer

As we saw with Pharmasset in 2011, Gilead Sciences paid a huge premium to acquire the company for a collection of assets. As an acquisition target, this is often what a company seeks. They want a late-stage proven candidate but also a host of other drugs in the pipeline that build on that technology.

Celldex Therapeutics, Inc. (NASDAQ:CLDX)

This fact makes Celldex Therapeutics, Inc. (NASDAQ:CLDX) especially attractive. The company has a breast cancer drug, CDX-011, that significantly increased survival in a population of seriously ill patients. This drug has been the basis for its 200% one-year gain, as it specifically targets an expression called GPNMB, and solidifies Celldex Therapeutics, Inc. (NASDAQ:CLDX) as a legitimate player in immunotherapy.

Then, the company has a Phase 3 drug, Rindopepimut, that treats brain cancer, and has shown consistent benefit in treating patients in three different Phase 2 studies. Moreover, the company has six products in clinical studies, all in treating cancer, making it a legitimate contender in the fight against cancer.

What makes Celldex Therapeutics, Inc. (NASDAQ:CLDX) attractive, aside from its pipeline, is the fact that it has been very successful at developing treatment regiments that maximize the immune system via targeted therapies, antibodies, and immune system modifiers. Its two late stage products, CDX-011 and Rindopepimut, have peak sales potential of $700 million and $500 million respectively; about equal to its current market capitalization.

When we try to find a potential suitor, you realize that it could be a dozen different companies. Celldex Therapeutics, Inc. (NASDAQ:CLDX) could create several approved products and billions in sales within the next five years. Roche, Merck, Amgen, Bristol-Myers, Johnson & Johnson (NYSE:JNJ), or just about any large pharma with an oncology program. If you consider that Celldex is trading at just one times peak sales – and the average acquisition is 3-4 times peak sales – you can see that Celldex Therapeutics, Inc. (NASDAQ:CLDX) could become attractive very quickly.

If you can’t beat them… Buy them!

Sometimes a product is so good that it causes potential acquirers to “think,” and wonder what a company’s patents and technology could create. Such is the case with ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD). Its drug Pimavanserin has succeeded in the treatment of Parkinson’s Disease psychosis and looks to be the best anti-psychotic in development right now; preparing to control a massive market.

Pimavanserin is also being tested to treat Schizophrenia and Alzheimer’s Disease psychosis, and combined could generate $1 billion in sales (or more). The company’s pipeline is not nearly as advanced as Celldex Therapeutics, Inc. (NASDAQ:CLDX), but it does have a promising pipeline for chronic pain, although it’s still too early to predict its likely outcome.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!